These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 17523243)

  • 21. Efficacy and safety of once-daily ritonavir-boosted darunavir and abacavir/lamivudine for treatment-naïve patients: a pilot study.
    Nishijima T; Tsukada K; Teruya K; Gatanaga H; Kikuchi Y; Oka S
    AIDS; 2012 Mar; 26(5):649-51. PubMed ID: 22233654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136.
    Katlama C; Valantin MA; Algarte-Genin M; Duvivier C; Lambert-Niclot S; Girard PM; Molina JM; Hoen B; Pakianather S; Peytavin G; Marcelin AG; Flandre P
    AIDS; 2010 Sep; 24(15):2365-74. PubMed ID: 20802297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Individualized therapy with fosamprenavir/r. A PI suitable in liver problems].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():60-1. PubMed ID: 19031566
    [No Abstract]   [Full Text] [Related]  

  • 24. Lopinavir/ritonavir. (Kaletra).
    Res Initiat Treat Action; 2000 Dec; 6(4):16-8. PubMed ID: 11708169
    [No Abstract]   [Full Text] [Related]  

  • 25. Combined protease results continue to hold up.
    McGuire S
    Posit Aware; 1997; 8(1):15. PubMed ID: 11364089
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fosamprenavir calcium plus ritonavir for HIV infection.
    Torres HA; Arduino RC
    Expert Rev Anti Infect Ther; 2007 Jun; 5(3):349-63. PubMed ID: 17547501
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-HIV agents. Monotherapy studies--points to consider.
    TreatmentUpdate; 2008 Jan; 20(1):3-4. PubMed ID: 18320692
    [No Abstract]   [Full Text] [Related]  

  • 29. Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients.
    Moltó J; Valle M; Santos JR; Mothe B; Miranda C; Cedeño S; Negredo E; Yritia M; Videla S; Barbanoj MJ; Clotet B
    Antivir Ther; 2010; 15(2):219-25. PubMed ID: 20386077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Different evidence of key amprenavir resistance mutations on the efficacy of darunavir.
    Di Biagio A; Rosso R; Bruzzone B; Cenderello G; Dentone C; Mularoni A; Ferrea G; Icardi G; Viscoli C
    AIDS; 2008 Jan; 22(3):437-8. PubMed ID: 18195574
    [No Abstract]   [Full Text] [Related]  

  • 31. FDA approves new dosing for amprenavir and ritonavir combination.
    AIDS Treat News; 2002 Mar; (378):6-7. PubMed ID: 11965920
    [No Abstract]   [Full Text] [Related]  

  • 32. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1.
    Katlama C; Esposito R; Gatell JM; Goffard JC; Grinsztejn B; Pozniak A; Rockstroh J; Stoehr A; Vetter N; Yeni P; Parys W; Vangeneugden T;
    AIDS; 2007 Feb; 21(4):395-402. PubMed ID: 17301557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients.
    Delaugerre C; Mathez D; Peytavin G; Berthé H; Long K; Galperine T; de Truchis P
    AIDS; 2007 May; 21(9):1210-3. PubMed ID: 17502734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Darunavir now approved for use in treatment-naive patients.
    Sax PE
    AIDS Clin Care; 2008 Dec; 20(12):102. PubMed ID: 19271337
    [No Abstract]   [Full Text] [Related]  

  • 35. FDA approves new PI.
    Gadd C
    IAPAC Mon; 2006 Jun; 12(6):174. PubMed ID: 17233103
    [No Abstract]   [Full Text] [Related]  

  • 36. [Preserving future therapy options. Darunavir--the protease inhibitor for various patient groups].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():24-5. PubMed ID: 19024912
    [No Abstract]   [Full Text] [Related]  

  • 37. Darunavir offers potent new combo when used with enfuvirtide in ritonavir-boosted regimen.
    Edmunds-Ogbuokiri T
    HIV Clin; 2007; 19(1):1-3. PubMed ID: 17405221
    [No Abstract]   [Full Text] [Related]  

  • 38. [Efficacy of atazanavir in treatment-naive patients].
    Moreno S; Hernández B; Dronda F
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():9-13. PubMed ID: 20116611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [HIV infection. Compatibility of recent protease inhibitors in direct comparison - the advantage of DRV].
    MMW Fortschr Med; 2014 Jun; 156 Suppl 1():52. PubMed ID: 25026859
    [No Abstract]   [Full Text] [Related]  

  • 40. [Maintaining independence. New protease inhibitor receives drug approval recommendation].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():84-5. PubMed ID: 15373062
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.